GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (STU:EXK) » Definitions » Shiller PE Ratio

Exact Sciences (STU:EXK) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Exact Sciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Exact Sciences Shiller PE Ratio Historical Data

The historical data trend for Exact Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Shiller PE Ratio Chart

Exact Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Exact Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Exact Sciences's Shiller PE Ratio

For the Diagnostics & Research subindustry, Exact Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Sciences's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Exact Sciences's Shiller PE Ratio falls into.



Exact Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Exact Sciences's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Exact Sciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.552/131.7762*131.7762
=-0.552

Current CPI (Mar. 2024) = 131.7762.

Exact Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.177 100.560 -0.232
201409 -0.303 100.428 -0.398
201412 -0.308 99.070 -0.410
201503 -0.370 99.621 -0.489
201506 -0.392 100.684 -0.513
201509 -0.401 100.392 -0.526
201512 -0.376 99.792 -0.497
201603 -0.440 100.470 -0.577
201606 -0.409 101.688 -0.530
201609 -0.321 101.861 -0.415
201612 -0.322 101.863 -0.417
201703 -0.299 102.862 -0.383
201706 -0.240 103.349 -0.306
201709 -0.193 104.136 -0.244
201712 -0.152 104.011 -0.193
201803 -0.268 105.290 -0.335
201806 -0.257 106.317 -0.319
201809 -0.317 106.507 -0.392
201812 -0.387 105.998 -0.481
201903 -0.584 107.251 -0.718
201906 -0.266 108.070 -0.324
201909 -0.281 108.329 -0.342
201912 0.486 108.420 0.591
202003 -0.824 108.902 -0.997
202006 -0.400 108.767 -0.485
202009 -1.146 109.815 -1.375
202012 -2.293 109.897 -2.750
202103 -0.151 111.754 -0.178
202106 -0.855 114.631 -0.983
202109 -0.825 115.734 -0.939
202112 -1.133 117.630 -1.269
202203 -0.944 121.301 -1.026
202206 -0.889 125.017 -0.937
202209 -0.848 125.227 -0.892
202212 -0.680 125.222 -0.716
202303 -0.392 127.348 -0.406
202306 -0.415 128.729 -0.425
202309 0.004 129.860 0.004
202312 -0.248 129.419 -0.253
202403 -0.552 131.776 -0.552

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Exact Sciences  (STU:EXK) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Exact Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences (STU:EXK) Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.